Literature DB >> 9058597

Involvement of activator protein-1 and nuclear factor-kappaB transcription factors in the control of the DT-diaphorase expression induced by mitomycin C treatment.

K S Yao1, A Hageboutros, P Ford, P J O'Dwyer.   

Abstract

The antitumor antibiotic mitomycin C is activated by several bioreductive enzymes, including DT-diaphorase. In HT29 cells, mitomycin C treatment results in the induction of DT-diaphorase as reflected in elevated steady state DT-diaphorase mRNA levels. An increase in the transcriptional rate was demonstrated by nuclear run-on assay. To investigate the molecular basis of the change in transcriptional activity caused by mitomycin C treatment, electrophoretic mobility shift assays were used to demonstrate the induction of nuclear factor binding to elements in the 5' flanking region of the DT-diaphorase gene. Treatment of HT29 cells with mitomycin C resulted in the dose-dependent induction of binding activity directed to the activator protein-1 (AP-1) binding element with a time course similar to that of mRNA elevation. Supershift assays using specific antibodies to Jun and Fos demonstrated the participation of both proteins in the binding activities generated. A binding activity for the nuclear factor-kappaB (NF-kappaB) site was induced with a similar time course. Both competitor and supershift experiments indicated that a heterodimer of the NF-kappaB proteins p50 and p65 was contained in the bound complex. To further investigate the functional consequences of such binding, we transfected HT29 cells with a plasmid containing 3 kb of the DT-diaphorase 5' region upstream of a reporter gene, chloramphenicol acetyltransferase. Treatment with mitomycin C resulted in a 5.5-fold increase in the expression of a chloramphenicol acetyltransferase construct containing 3 kb of DT-diaphorase promoter sequence. Using a series of deletion mutations based on this full-length construct, we found that two regions of the DT-diaphorase promoter region, positions -346 to -588 (containing the AP-1 element) and positions -785 to -890 (containing the NF-kappaB element) are required for the full expression of the mitomycin C response. The specific involvement of these binding elements was confirmed using mutational analysis. The results demonstrate that mutation of either element alone or of both diminishes the response, indicating an additive interaction between the elements at a minimum. However, inducibility characterizes a promoter fragment as small as 78 base-pairs from the transcription start site. Treatment of cells with mitomycin C induced binding to a 38-base-pair region (-40 to -78) devoid of known transcription factor binding elements. These data suggest that mitomycin C induces the overexpression of DT-diaphorase through a mechanism involving both the AP-1 and NF-kappaB response elements and that inducibility depends on a novel factor binding element.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9058597

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  4 in total

Review 1.  Crosstalk of reactive oxygen species and NF-κB signaling.

Authors:  Michael J Morgan; Zheng-gang Liu
Journal:  Cell Res       Date:  2010-12-28       Impact factor: 25.617

Review 2.  Redox regulation of DNA repair: implications for human health and cancer therapeutic development.

Authors:  Meihua Luo; Hongzhen He; Mark R Kelley; Millie M Georgiadis
Journal:  Antioxid Redox Signal       Date:  2010-06-01       Impact factor: 8.401

Review 3.  NF-kB as a key player in regulation of cellular radiation responses and identification of radiation countermeasures.

Authors:  Vijay Singh; Damodar Gupta; Rajesh Arora
Journal:  Discoveries (Craiova)       Date:  2015-03-31

4.  NQO1 overexpression is associated with poor prognosis in squamous cell carcinoma of the uterine cervix.

Authors:  Yue Ma; Jienan Kong; Guanghai Yan; Xiangshan Ren; Dan Jin; Tiefeng Jin; Lijuan Lin; Zhenhua Lin
Journal:  BMC Cancer       Date:  2014-06-09       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.